Global Venous Thromboembolism Therapeutics Market (2017-2021): 60-100,000 Individuals in the U.S. Die of VTE Every Year - Research and Markets

DUBLIN, Mar 21, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Venous Thromboembolism Therapeutics Market 2017-2021" report to their offering.

The global venous thromboembolism therapeutic market to grow at a CAGR of 6.40% during the period 2017-2021.

The global VTE therapeutics market is expected to benefit from the growing incidence of VTE worldwide. According to the CDC, every year around 0.9 million individuals are affected by VTE in the US and 60,000 to 100,000 individuals in the US die of VTE. Further, the presence of high unmet medical needs is expected to fuel the market growth. For instance, according to the CDC approximately 50% of individuals with VTE will have long-term complications, and 33% of individuals will have a recurrence within ten years.

The report, Global Venous Thromboembolism Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

One trend in market is development of drugs for new indications. The development of drugs for new indications will improve the sources of revenue generation and will likely drive the market growth. The vendors are extensively conducting research to develop drugs for hospitalized acute medically ill patients having risk of VTE. Till date, there is no approved drug for such patients. Therefore, many vendors such as Portola Pharmaceuticals are focusing on addressing that untapped market to drive growth and profitability.

Key vendors:

• Bayer HealthCare
• BMS
• Boehringer Ingelheim
• Daiichi Sankyo
• Johnson & Johnson
• Sanofi

Other Prominent Vendors:

• Altor Bioscience
• Armetheon
• Aspen Pharma
• BioInvent International
• eXIthera Pharmaceuticals
• Gamma Therapeutics
• Others
  

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Disease overview

PART 06: Pipeline analysis

PART 07: Market landscape

PART 08: Market segmentation by drug class

PART 09: Geographical segmentation

PART 10: Market drivers

PART 11: Impact of drivers

PART 12: Market challenges

PART 13: Impact of drivers and challenges

PART 14: Market trends

PART 15: Vendor landscape

PART 16: Key vendor analysis

PART 17: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/5r3ddn/global_venous

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[e-mail]

For E.S.T Office Hours Call [phone]
For U.S./CAN Toll Free Call [phone]
For GMT Office Hours Call [phone]

U.S. Fax: [phone]
Fax (outside U.S.): [phone]